Preclinical models of Waldenstrom's macroglobulinemia and drug resistance

被引：4

作者：

Ailawadhi, Sikander ^{[1
]}

Paulus, Aneel ^{[1
,2
]}

Chanan-Khan, Asher ^{[1
]}

机构：

[1] Mayo Clin Jacksonville, Div Hematol & Oncol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA

[2] Mayo Clin Jacksonville, Dept Canc Biol, 4500 San Pablo Rd, Jacksonville, FL 32224 USA

来源：

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY | 2016年 / 29卷 / 02期

关键词：

Waldenstrom's macroglobulinemia; Cell line; Preclinical; Resistance; NON-HODGKIN-LYMPHOMA; B-CELL LYMPHOMAS; LYMPHOPLASMACYTIC LYMPHOMA; BONE-MARROW; IN-VITRO; MONOCLONAL GAMMOPATHY; REGULATES SURVIVAL; 6Q DELETION; MICE; LINE;

D O I：

10.1016/j.beha.2016.08.017

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Newer therapeutic strategies are emerging in Waldenstrom's Macroglobulinemia (WM), which has traditionally been an orphan disease diagnosis. Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor was FDA-approved in 2015 as the first ever drug for the treatment of WM. This being a targeted therapy, has given rise to increased research into novel agents and pathways that can be exploited for clinical benefit in WM. In order to understand the underlying mechanisms of disease behavior as well as to test the benefit of various drugs, appropriate preclinical models are required. Historically there had been a lack of representative preclinical models in WM, but in recent years this has dramatically changed. This review highlights the currently available preclinical models and data regarding drug resistance pathways in WM. Knowledge from these will certainly help in paving the future course of treatment in this rare disorder which is indolent and yet, so far incurable. (C) 2016 Elsevier Ltd. All rights reserved.

引用

页码：169 / 178

页数：10

共 56 条

[1]

ALKATIB A, 1993, BLOOD, V81, P3034

[2] Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma [J].

Ansell, S. M. ;

Hodge, L. S. ;

Secreto, F. J. ;

Manske, M. ;

Braggio, E. ;

Price-Troska, T. ;

Ziesmer, S. ;

Li, Y. ;

Johnson, S. H. ;

Hart, S. N. ;

Kocher, J-P A. ;

Vasmatzis, G. ;

Chanan-Kahn, A. ;

Gertz, M. ;

Fonseca, R. ;

Dogan, A. ;

Cerhan, J. R. ;

Novak, A. J. .

BLOOD CANCER JOURNAL, 2014, 4 :e183-e183

[3] Non-Hodgkin Lymphoma: Diagnosis and Treatment [J].

Ansell, Stephen M. .

MAYO CLINIC PROCEEDINGS, 2015, 90 (08) :1152-1163

[4] Diagnosis and Management of Waldenstrom Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines [J].

Ansell, Stephen M. ;

Kyle, Robert A. ;

Reeder, Craig B. ;

Fonseca, Rafael ;

Mikhael, Joseph R. ;

Morice, William G. ;

Bergsagel, P. Leif ;

Buadi, Francis K. ;

Colgan, Joseph P. ;

Dingli, David ;

Dispenzieri, Angela ;

Greipp, Philip R. ;

Habermann, Thomas M. ;

Hayman, Suzanne R. ;

Inwards, David J. ;

Johnston, Patrick B. ;

Kumar, Shaji K. ;

Lacy, Martha Q. ;

Lust, John A. ;

Markovic, Svetomir N. ;

Micallef, Ivana N. M. ;

Nowakowski, Grzegorz S. ;

Porrata, Luis F. ;

Roy, Vivek ;

Russell, Stephen J. ;

Short, Kristen E. Detweiler ;

Stewart, A. Keith ;

Thompson, Carrie A. ;

Witzig, Thomas E. ;

Zeldenrust, Steven R. ;

Dalton, Robert J. ;

Rajkumar, S. Vincent ;

Gertz, Morie A. .

MAYO CLINIC PROCEEDINGS, 2010, 85 (09) :824-833

[5] Leukocyte analysis from WHIM syndrome patients reveals a pivotal role for GRK3 in CXCR4 signaling [J].

Balabanian, Karl ;

Levoye, Angelique ;

Klemm, Lysiane ;

Lagane, Bernard ;

Hermine, Olivier ;

Harriague, Julie ;

Baleux, Francoise ;

Arenzana-Seisdedos, Fernando ;

Bachelerie, Francoise .

JOURNAL OF CLINICAL INVESTIGATION, 2008, 118 (03) :1074-1084

[6] The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity [J].

Barretina, Jordi ;

Caponigro, Giordano ;

Stransky, Nicolas ;

Venkatesan, Kavitha ;

Margolin, Adam A. ;

Kim, Sungjoon ;

Wilson, Christopher J. ;

Lehar, Joseph ;

Kryukov, Gregory V. ;

Sonkin, Dmitriy ;

Reddy, Anupama ;

Liu, Manway ;

Murray, Lauren ;

Berger, Michael F. ;

Monahan, John E. ;

Morais, Paula ;

Meltzer, Jodi ;

Korejwa, Adam ;

Jane-Valbuena, Judit ;

Mapa, Felipa A. ;

Thibault, Joseph ;

Bric-Furlong, Eva ;

Raman, Pichai ;

Shipway, Aaron ;

Engels, Ingo H. ;

Cheng, Jill ;

Yu, Guoying K. ;

Yu, Jianjun ;

Aspesi, Peter, Jr. ;

de Silva, Melanie ;

Jagtap, Kalpana ;

Jones, Michael D. ;

Wang, Li ;

Hatton, Charles ;

Palescandolo, Emanuele ;

Gupta, Supriya ;

Mahan, Scott ;

Sougnez, Carrie ;

Onofrio, Robert C. ;

Liefeld, Ted ;

MacConaill, Laura ;

Winckler, Wendy ;

Reich, Michael ;

Li, Nanxin ;

Mesirov, Jill P. ;

Gabriel, Stacey B. ;

Getz, Gad ;

Ardlie, Kristin ;

Chan, Vivien ;

Myer, Vic E. .

NATURE, 2012, 483 (7391) :603-607

[7] WSU-WM and BCWM.1 should not be assumed to represent Waldenstrom macroglobulinemia cell lines [J].

Bergsagel, F. Leif ;

Kuehl, W. Michael .

BLOOD, 2008, 112 (03) :917-917

[8] CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88L265P-directed survival signalling in Waldenstrom macroglobulinaemia cells [J].

Cao, Yang ;

Hunter, Zachary R. ;

Liu, Xia ;

Xu, Lian ;

Yang, Guang ;

Chen, Jie ;

Tsakmaklis, Nickolas ;

Kanan, Sandra ;

Castillo, Jorge J. ;

Treon, Steven P. .

BRITISH JOURNAL OF HAEMATOLOGY, 2015, 168 (05) :701-707

[9] Emerging therapeutic options for Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma [J].

Chakraborty, Rajshekhar ;

Kapoor, Prashant ;

Ansell, Stephen M. ;

Gertz, Morie A. .

EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (10) :1143-1156

[10] Ibrutinib for the treatment of Waldenstrom macroglobulinemia [J].

Chakraborty, Rajshekhar ;

Kapoor, Prashant ;

Ansell, Stephen M. ;

Gertz, Morie A. .

EXPERT REVIEW OF HEMATOLOGY, 2015, 8 (05) :569-579

← 1 2 3 4 5 6 →